<DOC>
	<DOC>NCT01054924</DOC>
	<brief_summary>The purpose of the study is to evaluate efficacy (i.e. reaching the cecum) and safety of the Invendo C20 Colonoscopy System</brief_summary>
	<brief_title>Performance Study of the Invendo C20 Colonoscope System in Colorectal Cancer Screening</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1. Screenees, i.e. asymptomatic persons willing to undergo screening colonoscopy, at average risk for colorectal cancer 2. Age between 5075 years 3. Signed informed consent 1. Family or personal history of colorectal neoplasia including familial adenomatous polyposis (FAP) or hereditary nonpolyposis colorectal cancer 2. Prior colonoscopy within preceding 10 years 3. A suspected diagnosis of inflammatory bowel disease, bowel obstruction, acute diverticulitis, known severe diverticulosis or any known large bowel disease 4. Clinically significant cardiovascular or pulmonary diseases 5. Gastrointestinaltract related symptoms, complaints or diseases suggesting performance of colonoscopy (no screening cases) 6. Cancer or other life threatening diseases or significant chronic conditions 7. Blood clotting disorders and /or anticoagulant therapy including aspirin within the last 7 days 8. Known pregnancy or positive screening pregnancy tests 9. Previous abdominal surgery except for uncomplicated cholecystectomy, appendectomy or minor pelvic surgery (e.g. hernia repair, oophorectomy) 10. Morbid obesity (BMI &gt; 40) 11. Clinically significant abnormal screening laboratory findings 12. Clinically significant abnormal screening ECG findings 13. Drug abuse or alcoholism 14. Inability of the screenee to adequately communicate 15. Screenees under custodial care 16. Participation in a clinical study within the last 30 days</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>